The AmpliSeq for Illumina Immune Response Panel is a targeted resequencing research assay for quantitating expression of cancer biomarkers in 395 genes involved in tumor–immune system interactions. Key features include:
The Immune Response Panel is part of an integrated RNA-to-annotated variant solution that includes AmpliSeq for Illumina polymerase chain reaction (PCR)-based library preparation, Illumina sequencing by synthesis (SBS) next-generation sequencing (NGS) technology, and automated analysis.
This panel detects biomarkers associated with different leukocyte subsets, antigen presentation, checkpoint pathways, and tumor progression. The ready-to-use panel saves you the time and effort of identifying targets, designing primers, and optimizing panels.
Instrument | Recommended Number of Samples | Read Length |
---|---|---|
iSeq 100 System | 4 samples per run (assumes 1 million reads per sample) | 2 × 150 bp |
MiniSeq System | Samples per run: mid output: 8, high output: 24 (assumes 1 million reads per sample) | 2 × 150 bp |
MiSeq System | Samples per run (by reagent kit version): v2 micro: 4, v2: 15, v3: 24 (assumes 1 million reads per sample) | 2 × 150 bp |
AmpliSeq for Illumina Oncology Panels on the iSeq 100 System
Application note | PDF < 1 MB
Automated Solutions for AmpliSeq for Illumina Sequencing Panels
Application note | HTML
AmpliSeq for Illumina Immune Response Panel Gene List
product_file | EXCEL < 1 MB
Data sheet | PDF | 5 versions